Kumar, Shaji

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 4,978

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3,061

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 2,210

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,127

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 1,060

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,045

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 988

Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 983

Randomized trial of lenalidomide versus observation in smoldering multiple myeloma

Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A. M., Buadi, F. K., O’Brien, T., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 908

Multiple Myeloma: Diagnosis and Treatment

Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 812

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 648

Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance

Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V. (2018) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 647

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 628

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 616

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Kumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 446

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 370

Clinical Course of Patients With Relapsed Multiple Myeloma

Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings

Multiple Myeloma Research and TreatmentsMultiple Sclerosis Research Studies

Cited by 365

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 351

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., et al. (2007) · Leukemia

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 351

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 317

Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond

Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 305

The multiple myelomas — current concepts in cytogenetic classification and therapy

Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 302

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., Goldschmidt, H., et al. (2020) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 291

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network

Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 279